GFAP and glaucoma: Our results showed that GFAP mAb treatment mitigated glaucomatous neurodegeneration both structurally and functionally in vivo, by modulating astrogliosis and astrocyte-microglia activation to inhibit neuroinflammation in glaucoma, ultimately promoting RGC survival.